Eton Pharmaceuticals
Market Cap
US$110.4m
Last Updated
2019/12/08 00:31 UTC
Data Sources
Company Financials +
Executive Summary
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products.
Snowflake Analysis
High growth potential with adequate balance sheet.
Share Price & News
How has Eton Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ETON has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-6.7%
ETON
1.5%
US Pharmaceuticals
0.03%
US Market
1 Year Return
-2.9%
ETON
-0.1%
US Pharmaceuticals
18.6%
US Market
Return vs Industry: ETON underperformed the US Pharmaceuticals industry which returned -0.1% over the past year.
Return vs Market: ETON underperformed the US Market which returned 18.6% over the past year.
Shareholder returns
| ETON | Industry | Market | |
|---|---|---|---|
| 7 Day | -6.7% | 1.5% | 0.03% |
| 30 Day | 3.8% | -1.0% | 1.7% |
| 90 Day | 4.9% | 7.7% | 5.7% |
| 1 Year | -2.9%-2.9% | 2.5%-0.1% | 21.1%18.6% |
| 3 Year | n/a | 31.3%21.9% | 45.6%36.2% |
| 5 Year | n/a | 25.8%12.5% | 71.1%52.3% |
Price Volatility Vs. Market
How volatile is Eton Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
What Kind Of Investor Owns Most Of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)?1 month ago | Simply Wall St
We Think Eton Pharmaceuticals (NASDAQ:ETON) Needs To Drive Business Growth Carefully2 months ago | Simply Wall St
Who Has Been Buying Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares?Valuation
Is Eton Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ETON ($5.97) is trading below our estimate of fair value ($132.26)
Significantly Below Fair Value: ETON is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ETON is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: ETON is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ETON's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ETON is overvalued based on its PB Ratio (8.6x) compared to the US Pharmaceuticals industry average (3.1x).
Next Steps
Future Growth
How is Eton Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
62.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ETON is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: ETON is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ETON's is expected to become profitable in the next 3 years.
Revenue vs Market: ETON's revenue (65% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: ETON's revenue (65% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ETON's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Eton Pharmaceuticals performed over the past 5 years?
-127.1%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ETON is currently unprofitable.
Growing Profit Margin: ETON is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if ETON's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare ETON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ETON is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.3%).
Return on Equity
High ROE: ETON has a negative Return on Equity (-156.74%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Eton Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ETON's short term assets ($12.1M) exceed its short term liabilities ($1.1M).
Long Term Liabilities: ETON's short term assets ($12.1M) exceed its long term liabilities ($52.0K).
Debt to Equity History and Analysis
Debt Level: ETON is debt free.
Reducing Debt: ETON has not had any debt for past 5 years.
Balance Sheet
Inventory Level: ETON has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if ETON's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ETON has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ETON has less than a year of cash runway if free cash flow continues to reduce at historical rates of -49.3% each year
Next Steps
Dividend
What is Eton Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ETON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ETON's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ETON's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ETON's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ETON's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Eton Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
2.5yrs
Average board tenure
CEO
Sean Brynjelsen (47yo)
2.5yrs
Tenure
US$493,022
Compensation
Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice PÂ ...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD493.02K) is about average for companies of similar size in the US market ($USD508.62K).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
Board Age and Tenure
2.5yrs
Average Tenure
61yo
Average Age
Experienced Board: ETON's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 5,000 |
| Max Price | US$6.15 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 3,500 |
| Max Price | US$6.11 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 10,000 |
| Max Price | US$7.96 |
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 269.2%.
Management Team
Sean Brynjelsen (47yo)
President
- Tenure: 2.5yrs
- Compensation: US$493.02k
W. Troutman (64yo)
CFO, Treasurer & Secretary
- Tenure: 2.4yrs
- Compensation: US$296.55k
Bharathi Devarakonda
Senior Vice President of Regulatory Affairs & Product Development
- Tenure: 0yrs
Scott Grossenbach
Vice President of Sales & Marketing
- Tenure: 0yrs
Board Members
Paul Maier (71yo)
Independent Director
- Tenure: 2.3yrs
- Compensation: US$125.00k
Chuck Casamento (74yo)
Independent Director
- Tenure: 2.5yrs
- Compensation: US$125.00k
Norbert Riedel (61yo)
Chairman
- Tenure: 1.3yrs
- Compensation: US$125.00k
Mark Baum (46yo)
Director
- Tenure: 2.7yrs
- Compensation: US$125.00k
Sean Brynjelsen (47yo)
President
- Tenure: 2.5yrs
- Compensation: US$493.02k
Company Information
Eton Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Eton Pharmaceuticals, Inc.
- Ticker: ETON
- Exchange: NasdaqGM
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$110.404m
- Shares outstanding: 17.81m
- Website: https://www.etonpharma.com
Number of Employees
Location
- Eton Pharmaceuticals, Inc.
- 21925 West Field Parkway
- Suite 235
- Deer Park
- Illinois
- 60010
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ETON | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Nov 2018 |
Biography
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/08 00:31 |
| End of Day Share Price | 2019/12/06 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.